[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355991-105":59,"doc-detail-355991-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","b-ap15-enhances-trail-induced-cell-death-in-hnscc-via-the-induction-of-rosjnkdr5-signalling","b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling","","Therapeutic resistance to chemotherapy and radiotherapy remains a major challenge in head and neck squamous cell carcinoma (HNSCC), where the NFκB pathway promotes survival in response to TNFα and undermines cytotoxic treatment. This study evaluates whether the USP14/UCHL5 inhibitor b-AP15 sensitises HNSCC cells to TRAIL, revealing b-AP15-driven DR5 induction that depends on ROS and JNK signalling. The work also connects NFκB and XIAP downregulation to DR5 expression and shows synergistic effects with IAP antagonists in vitro.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/b-ap15-enhances-trail-induced-cell-death-in-hnscc-via-the-induction-of-rosjnkdr5-signalling/355991/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/b-ap15-enhances-trail-induced-cell-death-in-hnscc-via-the-induction-of-rosjnkdr5-signalling/355991.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main question addressed in this study?","Question",{"text":112,"@type":113},"Whether b-AP15 sensitises HNSCC cells to TRAIL-induced cell death in addition to sensitising them to TNFα and TNF-inducing therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does b-AP15 promote TRAIL sensitisation mechanistically?",{"text":117,"@type":113},"b-AP15 induces expression of the TRAIL receptor DR5 (TRAILR2), which requires ROS generation and activation of the JNK signalling pathway.",{"name":119,"@type":110,"acceptedAnswer":120},"What additional molecular link is proposed involving NFκB-dependent genes?",{"text":121,"@type":113},"b-AP15 reduces NFκB-dependent XIAP expression, supporting DR5 induction and enhancing TRAIL sensitisation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355991,1790210934,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Gene [Therapy](Therapy www.nature.com/cgt)[ www.nature.com/cgt](Therapy www.nature.com/cgt)  \nARTICLE OPEN   \nb-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling  \nFin T. A.  \nEthan L.  \nBrown 1,3, Lucy Quesne 1,3, Louisa M. Wootton 1, Holly Foxell1, Ipek Erseven1, Emilia Ewen Benns1, Molly Tate1 and  \n 1,2 ✉  \nMorgan   \n© The Author(s) 2026  \n\n|  | Therapeutic resistance to chemotherapy or radiotherapy is a signiﬁcant issue in several cancers, including head and neck squamous cell carcinoma (HNSCC) . One pathway associated with therapeutic resistance is the NFκB pathway, which promotes survival in response to the cytokine TNFα, a key mediator of chemotherapy and radiotherapy-induced cytotoxicity. However, direct targeting of the NFκB pathway is associated with signiﬁcant toxicity and thus targeting the regulation of this pathway is a promising therapeutic target. We recently demonstrated that the USP14/UCHL5 inhibitor b-AP15 inhibits NFκB activity, inhibiting proliferation and inducing apoptosis in HNSCC cells. Furthermore, b-AP15 treatment sensitised HNSCC cells to the cytotoxic effects of TNFα, as well as TNF-inducing radiation treatment. Here, we investigated if b-AP15 sensitised HNSCC cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a cancer selective member of the TNF family. b-AP15 treatment sensitised HNSCC cells to TRAIL treatment. Mechanistically, we show that b-AP15 induced expression of the TRAIL receptor Death Receptor 5 (DR5)/TRAIL Receptor 2 (TRAILR2), which was required for b-AP15-mediated TRAIL sensitisation. b-AP15 induced reactive oxygen species (ROS) and activated the JNK signalling pathway and both ROS and JNK signalling were required for the induction of DR5 expression and TRAILsensitisation. We further show that b-AP15-mediated reduction of the NFκB-dependent gene XIAP induced DR5 expression and TRAIL sensitisation and that combination between b-AP15 and IAP antagonists was synergistic in HNSCC cells in vitro. Our data further deﬁne the mechanism of b-AP15-mediated cytotoxicity and highlight potential combination treatments that warrant further |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| exploration in pre-clinical studies in HNSCC. |  |  |\n|  | Cancer Gene Therapy (2026) 33:533–546; [https://doi.org/10.1038/s41417-026-01038-3](https://doi.org/10.1038/s41417-026-01038-3) |  |\n|  |  |  |\n\nINTRODUCTION  \nHead and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, with over 900,000 new cases and 450,000 deaths worldwide per year [1] . HNSCCs include a range of cancers of the head and neck area, including cancers of the lip, oral cavity, larynx and hypopharynx [1] . HNSCC has been primarily associated with alcohol and tobacco use; however, an increase inhuman papillomavirus positive HNSCC (HPV + HNSCC) has been observed over the past two decades [2] . These two sub-types of HNSCC have signiﬁcantly different prognoses, with the ﬁve-year survival rate ranging between 28.8% and 58.7% for HPV- HNSCCand 52.2% and 77.6% for HPV-positive HNSCC, depending on the tumor subsite. Currently, standard treatment options include surgery, chemotherapy and radiotherapy, with limited treatment options for recurrent, metastatic HNSCC [2] . Furthermore, the side effects of standard treatments are often debilitating, necessitating the need for new treatment options that improve the survival outcomes in HPV- HNSCC to standard therapies, and aimed at deescalating treatment-associated toxicities in HPV + HNSCC [3, 4]. The cytotoxic effects of chemotherapy and radiotherapy are partially associated with the inﬂammatory cytokine TNFα [5, 6]. This cytokine induces cell death through multiple mechanisms but is often circumvented via activation of the NFκB pathway, which is a critical  \nregulator of survival an","cbCaimUxVTbsVago","https://ap.wps.com/l/cbCaimUxVTbsVago","pdf",5853457,14,"English","# Abstract and Background\n## Therapeutic resistance and NFκB rationale\n## Prior b-AP15 effects and study objective\n# TRAIL biology and study framework\n## TRAIL selectivity and receptor signaling","[{\"question\":\"What is the main question addressed in this study?\",\"answer\":\"Whether b-AP15 sensitises HNSCC cells to TRAIL-induced cell death in addition to sensitising them to TNFα and TNF-inducing therapies.\"},{\"question\":\"How does b-AP15 promote TRAIL sensitisation mechanistically?\",\"answer\":\"b-AP15 induces expression of the TRAIL receptor DR5 (TRAILR2), which requires ROS generation and activation of the JNK signalling pathway.\"},{\"question\":\"What additional molecular link is proposed involving NFκB-dependent genes?\",\"answer\":\"b-AP15 reduces NFκB-dependent XIAP expression, supporting DR5 induction and enhancing TRAIL sensitisation.\"}]","b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling | PDF",1790122119,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53ee53a462ab2a79f1fed9011a7ee920.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4cd088864e10080006a7817e6746d51.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79e7dca76eadb97850916a7b979fd87c.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52a06e7dd62d61b02f594873db539993.webp",980,1301]